NCT05228613View on ClinicalTrials.gov

Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018

PHASE1CompletedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

February 16, 2022

Primary Completion Date

August 2, 2022

Study Completion Date

January 24, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

SARS-CoV-2 protein subunit recombinant vaccine

candidate vaccine manufactured by PT. Bio Farma

BIOLOGICAL

SARS-CoV-2 inactivated vaccine

active control manufactured by Sinovac Life Sciences Co.Ltd

Trial Locations (2)

Unknown

Faculty of Medicine, Diponegoro University, Semarang, Semarang

Fakultas Kedokteran Universitas Indonesia, Jakarta

Sponsors

Lead Sponsor

PT Bio Farma
All Listed Sponsors
collaborator

Fakultas Kedokteran Universitas Indonesia

OTHER

collaborator

Faculty of Medicine, Diponegoro University, Semarang

UNKNOWN

lead

PT Bio Farma

INDUSTRY